Full Efficacy & Safety Summary Table
| Indication | Patients with elapsed MZL following at least 1 prior regimen |
| Registrational Trial | Accelerated Approval. Phase 2 single arm ULTRA-V trial (n=69) (NCT03801525) |
| Regimen | 800 mg orally once daily with food |
| Efficacy Outcomes | ORR: 49% / 16% CR |
| Safety Outcomes | Grade 3/4 AEs: Neutropenia 18%, Diarrhea Colitis: 9%, ALT/AST 9%, Pneumonia 3%, Sepsis 2%, UTI 2% N=221 patients pooled across trials |